

# Takeda Research & Development Fact Sheet

At Takeda, we are a forward-looking, world-class R&D organization that unlocks innovation and delivers transformative therapies to patients. By focusing R&D efforts on four therapeutic areas and other targeted investments, we push the boundaries of what is possible in order to bring life-changing therapies to patients worldwide.

## Our Focus Areas



### ONCOLOGY

We endeavor to deliver novel medicines to patients with cancer worldwide through our three strategic pillars: hematologic malignancies, lung cancer and immuno-oncology (I/O).



### RARE DISEASES

We aspire to transform the treatment of rare immunology, rare hematology and lysosomal storage disorders and expand our focus to bring transformative or curative therapies to other rare diseases.



### NEUROSCIENCE

Our mission is to bring innovative medicines to patients suffering from neurologic and psychiatric diseases for whom there are no treatments available.



### GASTROENTEROLOGY (GI)

We work to restore Life to Living for patients suffering with GI diseases across our core disease areas: inflammatory bowel disease, celiac and other luminal gut diseases, motility disorders and liver diseases.

## A Diverse & Dynamic Pipeline<sup>1</sup>



**~40**


NEW MOLECULAR ENTITY  
CLINICAL STAGE ASSETS



PIPELINE WITH ORPHAN  
DRUG DESIGNATION

### MODALITY-DIVERSE RESEARCH PROJECTS

Our Research engine is investing in next-generation technologies beyond small molecules to bring a new wave of innovative treatments to patients.



### PUTTING PATIENTS FIRST

Takeda's R&D patient access programs, knowledge sharing and capacity building programs have been recognized as **Industry Best Practices** by the Access to Medicine Foundation.

### R&D ESTABLISHED:

**20+**

PARTNERSHIPS

**50+**

INITIATIVES

with non-governmental organizations since 2015 to support local R&D and healthcare capacity building in underserved countries and communities.

### EXTERNALLY ORIENTED MINDSET

We seek innovation and partner to nurture it, wherever it resides. We have diverse partnership models, each created with aligned incentives and designed to leverage what we each do best - together.

Since FY16

**200+**

Active  
Partnerships

**45+**

Venture  
Investment  
Financings

**25+**

New Company  
Creations



## Our Global Footprint

### SAN DIEGO, CA

GI, Neuroscience,  
Discovery Technologies

### BOSTON, MA

R&D Center, Oncology,  
GI, Rare Diseases

### SHONAN, JAPAN

Neuroscience,  
Takeda & the  
Center for IPS  
Cell Research &  
Application, iPark



## Regional Centers\*



### OSAKA, JAPAN

TOKYO, JAPAN



### SHANGHAI, CHINA

SINGAPORE




### ZÜRICH, SWITZERLAND

VIENNA & ORTH, AUSTRIA

*\*Each regional center also has a secondary support team in the general vicinity to support local regulatory engagement and sustain other R&D activities.*

### LOCAL SITES

Takeda operates in additional countries for specific R&D functions and/or based on legal requirements.



## R&D Employees Globally

# ~4,500



## R&D Leadership Team



**Andy Plump**

President, Research  
& Development



**Chris Arendt**

Head, Oncology  
Therapeutic Area Unit



**Dan Curran**

Head, Rare Diseases  
Therapeutic Area Unit



**Sarah Sheikh**

Head, Neuroscience  
Therapeutic Area Unit



**Asit Parikh**

Head,  
Gastroenterology  
Therapeutic Area Unit



**Steve Hitchcock**

Head, Research



**Nenad Grmusa**

Head, Center for  
External Innovation



**Georgia Keresty**

R&D Chief  
Operating Officer



**Wolfram Nothaft**

Chief Medical  
Officer



**Stefan Wildt**

Head, Pharmaceutical  
Sciences & Translational  
Engine, Cell Therapies



**Jeremy Chadwick**

Head, Global  
Development Office



**Anne Heatherington**

Head, Data Sciences  
Institute



**Wolfgang Hackel**

Head, Global R&D  
Finance



**Erika Marder**

Head, Global R&D  
Human Resources



**Colleen Beauregard**

Head, Global R&D  
Communications



**Toshio Fujimoto**

General Manager,  
Shonan Health  
Innovation Park (iPark)